Literature DB >> 10793022

Changing incidence of glomerular diseases in adults.

G L Braden1, J G Mulhern, M H O'Shea, S V Nash, A A Ucci, M J Germain.   

Abstract

Studies performed at large metropolitan medical centers have reported an increasing incidence of idiopathic focal segmental glomerulosclerosis (FSGS) in adults. To determine whether a similar trend occurs in small urban and rural communities and to determine the role of race in these observations, we reviewed the patient records of all adults who underwent renal biopsies at our institution over the 20-year period from 1974 to 1994. The patients were grouped for analysis in 5-year intervals, 1975 to 1979, 1980 to 1984, 1985 to 1989, and 1990 to 1994, for the following diagnoses: FSGS, membranous nephropathy (MN), minimal change nephropathy (MCN), membranoproliferative glomerulonephritis (MPGN), immunoglobulin A (IgA) nephropathy, chronic glomerulonephritis, diabetic nephropathy, hypertensive nephrosclerosis, and chronic interstitial nephritis. Patients with secondary causes for these lesions were excluded. The relative frequency of FSGS increased from 13.7% during 1975 to 1979 to 25% during 1990 to 1994 (P < 0.05). The relative frequency of MN decreased from 38.3% during 1975 to 1979 to 14.5% during 1990 to 1994 (P < 0.01). There were no changes in the frequencies of MCN, MPGN, IgA nephropathy, chronic glomerulonephritis, diabetic nephropathy, hypertensive nephrosclerosis, or chronic interstitial nephritis over the 20-year period. However, there was a significant increase in the percentage of blacks with FSGS, from 0% in 1975 to 1979 to 22.6% in 1990 to 1994, and an increased percentage of Hispanics with FSGS, from 0% in 1975 to 1979 to 21.3% in 1990 to 1994 (P < 0.05). The modest increase in whites with FSGS did not reach statistical significance. The incidence of MN in blacks and whites decreased over the 20-year period. In the last 5 years, 15 patients per year had FSGS compared with 7 patients per year with MN (P < 0.05). No changes in age or sex between groups or over time accounted for these results. We conclude that FSGS is now diagnosed twice as often as MN and is the most common idiopathic glomerular disease at our hospital. Reasons for this increase include the emergence of FSGS in both Hispanics and blacks, with a modest increase of FSGS in whites. The increase in FSGS in the three most common races in our community suggests that factors other than genetic, perhaps environmental, have a role in the pathogenesis of FSGS.

Entities:  

Mesh:

Year:  2000        PMID: 10793022     DOI: 10.1016/s0272-6386(00)70258-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  72 in total

1.  Growth-dependent podocyte failure causes glomerulosclerosis.

Authors:  Akihiro Fukuda; Mahboob A Chowdhury; Madhusudan P Venkatareddy; Su Q Wang; Ryuzoh Nishizono; Tsukasa Suzuki; Larysa T Wickman; Jocelyn E Wiggins; Timothy Muchayi; Diane Fingar; Kerby A Shedden; Ken Inoki; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 10.121

2.  Discordant evolution of nephrotic syndrome in mono- and dizygotic twins.

Authors:  Gian Marco Ghiggeri; Monica Dagnino; Stefano Parodi; Cristina Zennaro; Antonio Amoroso; Francesco Pugliese; Francesco Perfumo
Journal:  Pediatr Nephrol       Date:  2005-12-29       Impact factor: 3.714

3.  Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity.

Authors:  Rajendra Bhimma; Miriam Adhikari; Kareshma Asharam
Journal:  Pediatr Nephrol       Date:  2006-09-12       Impact factor: 3.714

4.  MYO1E mutations and childhood familial focal segmental glomerulosclerosis.

Authors:  Caterina Mele; Paraskevas Iatropoulos; Roberta Donadelli; Andrea Calabria; Ramona Maranta; Paola Cassis; Simona Buelli; Susanna Tomasoni; Rossella Piras; Mira Krendel; Serena Bettoni; Marina Morigi; Massimo Delledonne; Carmine Pecoraro; Isabella Abbate; Maria Rosaria Capobianchi; Friedhelm Hildebrandt; Edgar Otto; Franz Schaefer; Fabio Macciardi; Fatih Ozaltin; Sevinc Emre; Tulin Ibsirlioglu; Ariela Benigni; Giuseppe Remuzzi; Marina Noris
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

Review 5.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

6.  Novel mutations in the inverted formin 2 gene of Chinese families contribute to focal segmental glomerulosclerosis.

Authors:  Jingyuan Xie; Xu Hao; Evren U Azeloglu; Hong Ren; Zhaohui Wang; Jun Ma; Jian Liu; Xiaodan Ma; Weiming Wang; Xiaoxia Pan; Wen Zhang; Fang Zhong; Yifu Li; Guoyu Meng; Krzysztof Kiryluk; John Cijiang He; Ali G Gharavi; Nan Chen
Journal:  Kidney Int       Date:  2015-06-03       Impact factor: 10.612

7.  A study of interobserver reproducibility of morphologic lesions of focal segmental glomerulosclerosis.

Authors:  Shane M Meehan; Anthony Chang; Ian W Gibson; Lisa Kim; Neeraja Kambham; Zoltan Laszik
Journal:  Virchows Arch       Date:  2012-12-21       Impact factor: 4.064

8.  FSGS as an Adaptive Response to Growth-Induced Podocyte Stress.

Authors:  Ryuzoh Nishizono; Masao Kikuchi; Su Q Wang; Mahboob Chowdhury; Viji Nair; John Hartman; Akihiro Fukuda; Larysa Wickman; Jeffrey B Hodgin; Markus Bitzer; Abhijit Naik; Jocelyn Wiggins; Matthias Kretzler; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2017-07-18       Impact factor: 10.121

9.  The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study.

Authors:  Musab S Hommos; An S De Vriese; Mariam P Alexander; Sanjeev Sethi; Lisa Vaughan; Ladan Zand; Kharmen Bharucha; Nicola Lepori; Andrew D Rule; Fernando C Fervenza
Journal:  Mayo Clin Proc       Date:  2017-10-27       Impact factor: 7.616

Review 10.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.